Abstract: Peptide profi les generated using SELDI/MALDI time of fl ight mass spectrometry provide a promising source of patient-specifi c information with high potential impact on the early detection and classifi cation of cancer and other diseases. The new profi ling technology comes, however, with numerous challenges and concerns. Particularly important are concerns of reproducibility of classifi cation results and their signifi cance. In this work we describe a computational validation framework, called PACE (Permutation-Achieved Classifi cation Error), that lets us assess, for a given classifi cation model, the signifi cance of the Achieved Classifi cation Error (ACE) on the profi le data. The framework compares the performance statistic of the classifi er on true data samples and checks if these are consistent with the behavior of the classifi er on the same data with randomly reassigned class labels. A statistically signifi cant ACE increases our belief that a discriminative signal was found in the data. The advantage of PACE analysis is that it can be easily combined with any classifi cation model and is relatively easy to interpret. PACE analysis does not protect researchers against confounding in the experimental design, or other sources of systematic or random error. We use PACE analysis to assess signifi cance of classifi cation results we have achieved on a number of published data sets. The results show that many of these datasets indeed possess a signal that leads to a statistically signifi cant ACE.
Introduction
High-throughput, low resolution time-of-fl ight mass spectrometry systems such as surface-enhanced laser desorption ionization -time of fl ight (SELDI-TOF) mass spectrometry (SELDI; Merchant and Weinberger, 2000; Issaq et al., 2002) and matrix-assisted laser desorption/ionization-time of fl ight mass spectrometry (MALDI) are just beginning to emerge as widely recognized high-throughput data sources for potential markers for the early detection of cancer (Wright et al., 1999; Adam et al., 2001; Petricoin et al., 2002) . Spectra, or peptide profi les, are readily generated from easily collected samples such as serum, urine, lymph, and cell lysates. Comparisons have been made for a large number of cancers (Table 1) in search of diagnostic markers, with astonishingly good initial results for the classifi cation of cancer and control profi les collected within respective studies.
With these very promising results the questions related to the signifi cance and reproducibility of such classifi cation results become imminent. Reproducibility and signifi cance are essential with these types of data since the identity of the peptides located at clinically signifi cant m/z positions that translate to the classifi cation accuracy are unknown and their correctness cannot be verifi ed through independent experimental studies.
The process of peptide profi le generation is subject to many sources of systematic errors. If these are not properly understood they can potentially jeopardize the validity of the results. Such concerns have led to the analysis of possible biases present in published data sets and questions on the reproducibility of some of the obtained classifi cation results under the proper experimental setup (Baggerly et al., 2004) . Such studies highlight the need for randomization of sample order acquisition and processing, maintaining constant protocols over the course of a study (including sample handling and storage conditions), identifi cation of potential confounding factors and the use of a balanced study design whenever possible to allow proper characterization of variation in the nondiseased population. Certainly, a design matrix should be created for each study and inspected for patterns that refl ect complete or severe partial incidental confounding. In addition, multi-site validation studies, which are currently ongoing in the EDRN (Early Detection Research Network), can help to identify possible problems.
The peptide profi le data are not perfect and include many random components. The presence of large amounts of randomness is a threat for interpretive data analysis; the randomness increases the possibility of identifying a structure and patterns in a completely uninformative signal. In such a case we want to have an additional assurance that the data and results of interpretive (classifi cation) analysis obtained for these data are not due to chance. Permutation tests (Kendall, 1945; Good, 1994) used commonly in statistics offer one solution approach to this problem and allow us to determine the signifi cance of the result under random permutation of target labels. In this work, building upon the permutation test theory, we propose a permutation-based framework called PACE (Permutation-Achieved Classifi cation Error) that can assess the signifi cance of the classifi cation error for a given classifi cation model with respect to the null hypothesis under which the error result is generated in response to random permutation of the class labels.
The main advantage of the PACE analysis is that it is independent of the model design. This allows the problems of choosing the best disease prediction model and achieving a signifi cant result to become decoupled. Many of the methods of high-throughput data analysis are very advanced, and thus may be poorly understood by the majority of researchers who would like to adopt a reliable analysis strategy. Understanding PACE analysis involves only visual examination of an intuitive graph (e.g, Figure 1 ), which makes it easy to apply and explain to the novice.
In the following we fi rst describe the classifi cation problem and evaluation of the classifi cation performance. Next we introduce the PACE framework that offers additional assessment of the signifi cance of the results. We compare PACE conceptually to existing confi dence assessment methods; it is found to be potentially complementary to confi dence interval-based bootstrap methods, which seek to determine whether a confi dence interval around a statistic of interest includes a single point (or a series of single points; i.e, the ROC curve). Finally, we apply PACE analysis to a number of published and new SELDI-TOF-MS data sets. We demonstrate with positive and negative results the utility of reporting not only the ACE but also whether a given ACE is statistically signifi cant. PACE thus provides a beginning reference point for researchers to determine objectively whether they have constructed a signifi cant classifi er in the discovery phase.
Evaluation of classifi ers

Classifi cation
Classifi cation is the task of assigning class "labels" to sample data which come from more than Ovarian Cancer 100%, 95% Petricoin et al., 2002 Prostate Cancer 100%, 100% Qu et al., 2002 Breast Cancer 90%, 93% Vlahou et al., 2003 Breast Cancer 91%, 93% Li et al., 2002 Head & Neck Cancer 83%, 90% Wadsworth et al., 2004 Lung Cancer 93.3%, 96.7% Xiao et al., 2003 Pancreatic Cancer 78%, 97% Koopmann et al., 2004 one category. In our case, the classifi cation task is to determine whether a particular proteomic profi le comes from a case (cancerous) or control (non-cancerous) population. A classification model which assigns labels (either case or control) to profi les can be learned from training examples; profi les with known case and control labels. The goal is to achieve a classifi er that performs as best as possible on future data. Practical concerns related to the classifi er learning include the possibility of model overfi t. The overfi t occurs when the classifi cation model is biased strongly towards training examples and generalizes poorly to new (unseen) examples. Typically, model overfit occurs due to the inclusion of too many parameters in the model in conjunction with a small number of examples. To assess the ability of the classifi cation model to future data we can split the data from the study into training and test sets; the training set is used in the learning stage to build the classifi er, the testing set is withheld from the learning stage and it is used for evaluation purposes only.
Evaluation
Training set: a collection of samples used to identify features and classifi cation rules based on discriminatory information derived from the comparisons of features between or among groups.
Test set: a collection of samples to which the classifi cation rules learned from the training set are applied to produce an estimate of the external generalizability of the estimated classifi cation error. The classifi cation error rate observed when classifi er is applied to them is called the test error rate. (Similarly, the sensitivity is called test set sensitivity, etc.). The classifi er rules learned include parameters optimized using the training set that are then included in the prediction phase (for predictions on the test set). Test errors are usually higher than the training errors; Feng et al. refer to the difference as 'optimism'; (Z. Feng, personal communication) . Test errors are less biased than training errors, and therefore are more (but not completely) refl ective of the expected classifi cation error should the classifi er be applied to new cases from the same population. The use of the test data set errors as the estimate is appropriate because it is low-biased compared to the classifi cation errors achieved using only the training data set. The test set may be a held-out set of samples, or, more commonly, a number of held-out sets to avoid inaccuracy of ACE.
Validation set: a set of samples collected and/or processed and/or analyzed in a laboratory or at a site different from the laboratory or site where the original training sets were produced. Validation sets are never included in the learning step. All validation sets are test sets but not all test sets are validation sets. The more independence there is among sample sets, laboratory protocols, and implementation of a particular method of predicting class membership, the more robust the biomarkers.
Cross-validation
Methods for estimating the test error include leave-one-out cross-validation, k-fold validation, and random subsampling validation. The selection of each of these depends in part on the number of samples available; these methods and their suitability for application to the analysis of highthroughput genomic and proteomic data sets have recently been explored (Braga-Neto & Dougherty, 2004) . Use of the test error rates and performance measures derived from those rates allows one to assess the expected sensitivity (SN) and specifi city (SP) of a given test or classifi er; these performance measures are usually summarized in a confusion matrix. Even with these estimated performance measures, however, a more general question remains: for a broad range of potential outcomes and focus, from biomarker evaluation, discovery, validation and translation, what level of sensitivity is to be deemed signifi cant, or suffi cient, at a specifi ed level of specifi city? The clear overall objective of maximizing both SN and SP is built into the receiver-operator-characteristic (ROC) evaluation of a test, and the search of the most informative test usually seeks to maximize the area under the curve (AUC). Estimates of SN, SP, the ROC curve, and its area can all be determined using random subsampling validation. These approaches are well-studied, and their estimates of expected classifi cation error are generally understood to be less biased than those estimated using training data sets.
Permutation-based validation
The individual performance statistics by themselves, do not always allow us to judge the importance of the result. In particular, one should be always concerned by the possibility that the observed statistic is the result of chance. Careful elimination of this possibility gives more credibility to the result and establishes its potential importance. Permutation test methods offer a class of techniques that make this assessment possible under a wide variety of assumptions. Expected performance under the null model varies with the specifi cs of a design, and the distribution of the performance statistics vary with the distribution of information among markers and the type of disease prediction model used.
Permutation test methods work by comparing the statistic of interest with the distribution of the statistic obtained under the null (random) condition. Our priority in predictive models is to critically evaluate the observed discriminatory performance. In terms of hypothesis testing the null hypothesis we want to reject is:
The performance statistic of the disease prediction model on the true data is consistent with the performance of the model on the data with randomly assigned class labels.
The objective of optimizing a classifi cation score itself is largely uncontrolled in most genomic and proteomic high-throughput analysis studies. Researchers do not, for example, typically attempt to determine and therefore do not report the statistical signifi cance of the sensitivity of a test, in spite of the existence of a number of approaches for performing such assessments. Here we introduce a permutation method for assessing signifi cance on the achieved classifi cation error (ACE) of a constructed prediction model.
Theory
A permutation test is a non-parametric approach to hypothesis testing, which is useful when the distribution for the statistic of interest T is unknown. By evaluating a classifi er's statistic of interest when presented with data having randomly permuted labels, an empirical distribution over T can be estimated. By calculating the p-value of the statistic's value when the classifi er is presented with the true data, we can determine if the classifi er's behavior is statistically signifi cant with respect to the level of confi dence α.
Let
be a set of all permutations of labels of the dataset with d examples. The permutation test (Mukherjee et al., 2003) is then defi ned as:
• Repeat N times (where n is an index from 1, ..., N)
• Choose a permutation For our purposes, the statistic of interest T is the achieved classifi cation error (ACE).
Application of permutation-based validation to peptide profi ling (PACE)
We defi ne a classifi cation method f as all steps applied by a researcher to the data prior to some biological interpretation. These include the steps summarized in Table 2 . In the case of SELDI/ MALDITOF-MS, this may include mass calibration, baseline correction fi ltering, normalization, peak-selection, a variety feature selection and classifi cation, approaches. We take the position that every researcher that has decided to approach the problem of analysis of a high-throughput proteomic data set has embarked on a journey of method development; i.e, the series of decisions made by the research itself is method f.
We assume that the researcher has adopted a study design that employs one or more training/test set splits, For our purposes, we use 40 random training/test splits to achieve a reasonably accurate estimate of ACE. A third validation sample can be set aside to verify the statistic on the pristine data. The validation set can either be produced at the same time, under the same conditions as the 
Data Representation
Determination of profi le attributes:
May also include peak-fi nding algorithms and peak-matching routines
Feature Selection
Identifi cation of profi le features which are likely to be clinically signifi cant:
Classifi cation
Rendering sample class inferences
Computational Validation / Study Design
Calculation of an estimated classifi cation error rate which is hopefully unbiased and accurate. May involve:
• Random subsampling
• Bootstrapping
Signifi cance Testing of ACE PACE (this paper) Boostrap confi dence interval estimation (Efron and Tibshirani, 1997) training/test data set. A more general estimate of the external validity of the estimate of the generalization error and its robustness to different laboratory conditions (and thus an assessment of the potential for practical (clinical) application) is obtained when the validation set is obtained at a different time or better yet in a different laboratory (as in multisite validation studies).
Permutation-Achieved Classifi cation Error (PACE) Analysis
Given the achieved classifi cation error (ACE) estimated via method f, generate an arbitrarily large number of new data sets with random sample relabeling. Method f is applied to each of the permuted data sets, resulting in a null distribution of ACE (called PACE). Lower 95th and 99th percentiles are located in PACE: ACE is then compared to these percentiles to assess the statistical significance of the classifi er method f.
Alternatives to PACE
The permutation-based approach compares the error achieved on the true data to errors on randomly labeled data. It tries to show that the result for the true data is different from results on the random data, and thus it is unlikely the consequence of a random process. We note that the permutation-based method is different and thus complementary to standard hypothesis testing methods that try to determine confi dence intervals on estimates of the target statistics. We also note that one may apply standard hypothesis testing methods to check if the target statistic for our classifi cation model is statistically signifi cantly different from either the fully random, trivial or any other classifi cation model. However, the permutation framework always looks at the combination of the data label generation and classifi cation processes and thus establishes the difference in between the performance on the true and random data.
Classifi cation error is a composite evaluation metric. Other types of performance measures for which confi dence intervals have been studied so far include signifi cance of SN at a fi xed SP (Linnet, 1987) , AUC (as implemented, for example, in Accu-ROC; Vida, 1993) , and the ROC curve itself (Macskassy et al., 2003) . Here we briefl y explain these options. Which performance measure to assess may vary according to strategy. Bootstrapestimated or analytically determined confi dence intervals around SN at a specifi ed SP (Linnet, 1987) requires that a desired SP be known, and this depends on its intent; for example a screening test should have very high SP to avoid resulting in too many false positives when applied to a population. Even here, however, "very high" and "too many" are rather context-dependent, should not be considered in a silo by ignoring existing or other proposed diagnostic tests. Acceptable FP values depend to a degree on the SP of existing practices, and to an extent on the prevalence of the disease. Any screen can be considered to change the prevalence of disease in the 'potential patient' population, and therefore follow-up with panels of minimally invasive markers, or multivariate studies th and 99 th percentiles of the PACE distribution are given by the dashed and dotted lines, respectively. If the achieved classifi cation error (ACE, bottom marked line) falls below a percentile band, it is a statistically signifi cant result at that confi dence level. In this example, ACE for a Naïve Bayes classifi er using a weighted separability without peak selection or de-correlation (see below for details) falls consistently below the 99 th percentile band of the PACE distribution. It can be said that this classifi er produced a statistically signifi cant result at the 99% level.
of numerous risk factors (demographic, familial, vaccination, smoking history), and long-term monitoring, might make such screening worthwhile. High-throughput proteomics highlights the need for dynamic clinical diagnostics.
The various approaches suggested by Linnet were extended and revised with a suggestion by Platt et al. (2000) to adopt the bootstrap confi dence interval method (Efron and Tibshirani, 1993) . A working paper by Zhou and Qin (2003) explores related approaches. One strategy is to perform bootstrapping (Efron and Tibshirani, 1993) and calculate a 1-α confi dence interval around a measure of interest. Bootstrapping is a subsampling scheme in which N data sets are created by subsampling the features of the original data set, with replacement. Each of the N data sets is analyzed. Confidence intervals around some measure of interest (T) can be calculated or consensus information can be gathered; in either case, variability in an estimate T is used a measure of robustness of T. Various implementations of the bootstrap are available; the least biased appears to be bias-corrected accelerated version (Efron and Tibshirani, 1993) .
A second strategy is to calculate confidence intervals around the AUC measure. Bootstrapping (Efron and Tibshirani, 1997 ) is sometimes used to estimate AUC confi dence intervals. Relying on confi dence in the AUC can be problematic because it reports on the entire ROC, and, in practice, only part of the ROC is considered relevant for a particular application (e.g, high SP required by screening tests. A literature on assessing the signifi cance of partial ROC curves has been developed (Dodd and Pepe, 2003; Gefen et al., 2003) ; a recent study (Stephan, Wesseling et al., 2003) compared the features and performance of eight programs for ROC analysis.
A third strategy is to calculate bootstrap confidence bands around the ROC curve itself (Macskassy et al., 2003) . Under this approach, boot strapping is explored and bands are created using any of a variety of 'sweeping' methods that explore the ROC curve in one (SN) or two (SN and 1-SP) dimensions.
Experimental results of PACE analysis on clinical data
We applied PACE analysis to the following published data sets, and one new data set from the UPCI, using a number of methods of analysis:
• UPCI Pancreatic Cancer Data • Ovarian Cancer Data (D1; Petricoin et al., 2002) • Ovarian Cancer Data (D2; Petricoin et al., 2002) • Prostate Cancer Data The UPCI's pancreatic cancer data are only in the preliminary stages of analysis and we report only initial results. An ongoing study with an independent validation set is underway. Preoperative serum samples were taken from 32 pancreatic cancer cases (17 female, 15 male). Twenty-three non-cancer age, gender, and smoking history-matched controls were analyzed; ages ranged from 34 to 87, pancreatic cancer cases had a mean age of 64, controls had a mean age of 67 (p=0.19). Of the cancer samples, 16 were resected; 6 patients had locally advanced unresectable disease, and 10 had metastatic disease.
The ovarian cancer datasets D1 and D2 (Petricoin et al., 2002) were obtained through the clinical proteomics program databank (http:// ncifdaproteomics.com/). Both datasets were created from the same samples, but D2 was processed using a different chip surface (WCX2) as opposed to the hydrophobic H4 chip used to generate the data in D1. The samples consist of 100 controls: 61 samples without ovarian cysts, 30 samples with benign cysts smaller than 2.5 cm, 8 samples with benign cysts larger than 2.5 cm, and 1 sample with benign gynecological disease. The samples include 100 cases: 24 samples with stage I ovarian cancer, and 76 samples with stage II, II and IV ovarian cancer.
The prostate cancer dataset was also acquired from the clinical proteomics program databank. It consists of 253 controls: 75 samples with a prostate-specifi c antigen (PSA) level less than 4 ng/ML, 137 samples with a PSA level between 4 and 10 ng/ML, 16 samples with a PSA level greater than 10 ng/ML, and 25 samples with no evidence of disease and PSA level less than 1 ng/ML. 69 cases exist in this dataset: 7 samples with stage I prostate cancer, 31 samples with stage II and III prostate cancer, and 31 samples with biopsy-proven prostate cancer and PSA level greater than 4 ng/ML. Table 3 gives a summary of methods applied in the analysis. A brief description of some of these methods is provided below. A thorough description of these methods can be found in Hauskrecht et al. (2005, in press ).
Methods Applied and Evaluated
Peak detection
In some circles it is a strong belief that only peaks in a profi le represent informative features of a profi le. Peak detection can take place before performing further feature selection in order to limit the initial amount of the profi le to be considered. There are various ways in which peak detection can be performed; for the purposes of our experiments, we utilize a peak detection method that examines the mean profi le generated for all training samples, and then determines its local maxima. The local maxima positions become the only features considered for feature selection later in the pipeline displayed in Table 3 . Alternatively, we can ignore the peak detection phase completely and consider the entire profi le for feature selection.
Feature selection methods
Fisher Score: The Fisher score is intended to be a measure of the difference between distributions of a single variable. A particular feature's Fisher score is computed by the following formula:
where μ i ± is the mean value for the i th feature in the positive or negative profi les, and σ i ± is the standard deviation. We utilize a variant of this criterion (Furey, 2000) , computed with the following formula:
To avoid confusion, we refer to the second formula above as our "Fisher-like score". Features with high Fisher scores possess the desirable quality of having a large difference between means of case versus control groups, while maintaining low overall variability. These features are more likely to be consistently expressed differently between case and control samples, and therefore indicate good candidates for feature selection.
AUC Score (for feature selection): Receiver operating characteristic curves are commonly used to measure the performance of diagnostic systems in terms of their "hit-or-miss" behavior. By computing the ROC curve for each feature individually, one can determine the ability of that feature to separate samples into the correct groups. Measuring the area under the ROC curve (Hanley et al., 1982) then gives an indication of the feature's probability of being a successful biomarker. The AUC score for a given feature is then obtained by integrating over the ROC curve for that feature. As with the Fisher score, higher AUC scores signify better feature candidates.
Univariate t-test:
The t-test (Baldi et al., 2001) can be used to determine if the case versus control distributions of a feature differ substantially within the training set population. The t statistic, representing a normalized distance measurement between populations, is given as De-correlation Enhancement We also evaluated feature selection using simple separability, weighted separability, and the J5 test (Patel and Lyons-Weiler, 2004 ).
De-correlation enhancement:
After differential feature selection, we can perform further feature evaluation to avoid highly correlated features. These may be of interest for interpreting the biological sources of variation among peptides (such as carrier proteins; Mehta et al., 2003) . For the purpose of constructing independent classifi ers, however, it may be better to avoid using non-independent features -if only to increase the number of features included after feature selection -but also to avoid overtraining on a large number of highly correlated features. One way to avoid these correlated features is de-correlation (removal of features which are inter-correlated beyond some pre-determined threshold). All of the methods described so far can be evaluated with and without de-correlation.
Principal component analysis:
Principal component analysis, a type of feature construction, incorporates aspects of de-correlation by grouping correlated features into aggregate features (components), which are presumed to be orthogonal (i.e, uncorrelated).
Classifi cation models
Naïve Bayes: The Naïve Bayes classifi er makes the assumption that the state of a feature (indicating membership in the case or control group) is independent of the states of other features when the sample's class (case or control) is known. Let
be a sample consisting of n features, and
be a set of m target classes to which X might belong. One can compute the probability of a sample belonging to a particular class using Bayes' rule:
The likelihood of sample X belonging to a particular target class c j is given as the product of each probability density function for each feature in the population of c j .
For our purposes, we assume each feature x k follows a Gaussian distribution, although other distributions are possible. Thus, the probability density function for feature x k is These two values, and their corresponding pair for the control population, must be estimated using the empirical information seen in the training set for each feature. The estimates are then used in the computation above during the predictive process on the testing set.
Support Vector Machine (SVM):
One might imagine a sample with n features as a point in an n-dimensional space. Ideally, we would like to separate the n-dimensional space into partitions that contain all samples from either case or control populations exclusively. The linear support vector machine or SVM (Vapnik 1995 , Burges 1995 
PACE Results
All four cancer datasets were analyzed using classifiers defined by differing configurations of feature selection criteria, peak selection, decorrelation, and classifi cation models. De-correlation MAC thresholds range from 1 (no de-correlation) to 0.4 (strict de-correlation) in increments of 0.2. To assess the statistical signifi cance of the classifi ers generated through these confi gurations, PACE analysis was performed using 100 random permutations of the data over 40 splits into training and testing sets. Classifi ers were evaluated over the range of 5 to 25 features, in increments of 5 features.
For illustrative purposes, examples of PACE graphs are presented in the appendices of this work. These graphs represent only a portion of the classifi ers evaluated for this work. In particular, the appendices present PACE graphs for SVM classifi ers enforcing a 0.6 MAC threshold, both before and after peak selection, for each of the univariate feature selection methods.
UPCI Pancreatic Cancer Data
Each possible configuration of classification models produced a statistically signifi cant classifi er at the 99% level. This trend was observed for all feature sizes in each classifi er. See fi gures A.1 through A.6 for examples of PACE analysis on this dataset using different feature selection criteria.
Ovarian Cancer Data (D1; Petricoin et al., 2002) Each possible configuration of classification models produced a statistically signifi cant classifi er at the 99% level. This trend was observed for all feature sizes in each classifi er. See fi gures B.1 through B.6 for examples of PACE analysis on this dataset using different feature selection criteria.
Ovarian Cancer Data (D2; Petricoin et al., 2002) Each possible confi guration of classifi cation models produced a statistically signifi cant classifi er at the 99% level. This trend was observed for all feature sizes in each classifi er.
See fi gures C.1 through C.6 for examples of PACE analysis on this dataset using different feature selection criteria.
Prostate Cancer Data Under random feature selection, several classifi ers were produced which were not statistically signifi cant at the 99% or 95% level. Using the Naïve Bayes classifi cation model, the generated classifi ers were not signifi cant at the 95% level for small amounts of features (5-15). As de-correlation becomes stricter, the classifi ers lost statistical signifi cance at high amounts of features where they had been signifi cant with a more lenient MAC. When coupling this technique with peak selection, no statistically signifi cant classifi ers were produced. With an SVM-based classifi er using random feature selection, the produced classifi ers were signifi cant at the 99% level except when using the initial 5 features. Changes in MAC and peak selection did not change this behavior.
In general, Naïve Bayesian classifi ers using univariate feature selection criteria are signifi cant at the 99% level as long as peak selection is not performed beforehand. The one exception was the J5 test, which was unable to produce a signifi cant classifi er at the 95% level without the aid of de-correlation. Applying de-correlation allowed these classifi ers to achieve signifi cance at the 99% level. When performing peak selection, only the classifiers produced using the strictest MAC thresholds (0.6, 0.4) were able to achieve some form of signifi cance, and even then, only at high amounts of features (15-25). The weighted separability score was unable to produce a signifi cant naïve Bayes classifi er using peak selection.
SVM classifi ers using univariate feature selection criteria were nearly always signifi cant at the 99% level, either with or without peak selection. The few instances where there was no signifi cance at the 95% level occurred using the J5 and simple separability scores without de-correlation. In the case of the J5 score, lowering the MAC to 0.8 remedied the situation, while the simple separability score improved simply through incorporating additional features.
See fi gures D.1 through D.6 for examples of PACE analysis on this dataset using different feature selection criteria.
Discussion
We have before us a daunting challenge of creating conduits of clear and meaningful communication and understanding between 'consumers' (statisticians, computational machine learning experts, bioinformaticians) and the producers of high throughput data sets. The objective is to maximize the rate at which clinically signifi cant patterns can be discovered and validated. Disciplines can be bridged in part by a straightforward reference point on performance provided by decision-theoretic performance measures. Nevertheless, performance characteristics that are typically reported (SN, SP, PPV, NPV) only provide partial information on performance (the method's performance in the alternative case). Researchers may be reluctant to publish results that have 'relatively low' SN and SP (e.g, 0.75, 0.8), and yet this level of performance may in fact be highly surprising given the sample numbers and degree of variability (due to noise variance). Stellar results such as high 90's sensitivity and specifi city predominate in the published cancer literature (Table 1) , posing the question of whether the early reports of high performance may have set the standard too high. Some biological signal and powers of prognosis can be expected to be lower. Our work focuses on the question: what represents a remarkable SN? SP? AUC? ACE? We study this from the perspective that proteomic profi ling represents only one of many different sources of potential clinically signifi cant information, and that combined use of panels of biomarkers and other molecular and classical diagnostic information is likely to be required if proteomic profi ling becomes widely adopted.
Minimize ACE: Conjecture or Tautology?
In microarray analysis, most papers describe a new algorithm or test for fi nding differentially expressed genes. This makes is diffi cult to assess the validity of a given analytical strategy (method of analysis). We recommend that a standard be considered for the assessment of the impact of particular decisions in the construction of an analytical strategy, including decisions made during pre-processing (Figs. 2 and 3): Specifi cally,
Any method that results in a signifi cant ACE is to be preferred over methods that do not achieve signifi cance. All signifi cant methods (at a specifi ed degree of signifi cance) are equally justifi ed -for the time being.
It is possible that different methods that achieve signifi cant ACE will identify distinct feature sets, in which case each feature set is potentially interesting.
Note that we are not suggesting that reproducibility is not important; i.e, ideally, the same methods on similarly-sized different data sets should achieve similar levels of signifi cance. Indeed, reproducibility is key; therefore, the methods that yield similar levels of signifi cance in repeated experiences are also validated.
Note also that we are also not recommending that one should adopt the somewhat opposing position that
The method that minimizes ACE will tend to be most signifi cant, and therefore will likely be best justifi ed.
In contrast, we consider it likely that clinically signifi cant information may exist at a variety of scales within these large data sets. The search for a method-any method-with the most signifi cant ACE from a single data set seems likely to lead to overestimates of the expected clinical utility of a set of biomarkers. Comparisons of ACE across cancer types and with independent data set would be informative.
Nonsignifi cant Results
Reasons for negative results might include no biological signal, poor study design or laboratory SOPs, poor technology, or low biological signal (requiring larger numbers of samples). It is our position that researchers are better informed whether the result is signifi cant or not. For example, a non-significant ACE may inform the researcher that they should refi ne or redirect their research question; an example might include early detection of a given disease providing a negative result in the pre-disease state, suggesting that one might move the focus to early stage disease instead of pre-disease. While the clinical prediction of a potential outcome during the course of disease may not be possible from the preconditioned state, the research might shift focus toward 'how early can this condition be predicted?' While we report few non-significant results, we have seen nonsignifi cant results from unpublished, proprietary studies of which we cannot report the details. The results are unpublished in part due to the negative results, and in part due to the changes in the experimental design that has resulted due to achieving a negative result.
Relation of PACE to Similar Methods
PACE creates a distribution of the expected ACE under the null condition. The fi xed measure ACE is the average classifi cation error over all random sub-samplings. This generates a distribution around ACE, and the determination of signifi cance could involve a comparison of the degree of overlap between the ACE and PACE distributions. As we have seen, PACE is similar in focus to a number of alternative methods with slightly distinct implementations and foci. These include the ROC bootstrap confidence interval on AUC, confidence interval estimation around SN at a fi xed SP, and bootstrap bands around the ROC curve itself. The bootstrap ROC is used to determine a confi dence interval around an estimated area under the ROC curve (AUC); we are most interested in the specifi c part of feature space where a classifi er works best, not in the overall performance of a classifi er over a range of stringency, and thus PACE focuses on comparing a point estimate of statistic theta to its null distribution. A traditional limitation of permutation tests is an assumption of symmetry; in our case, we are only interested in the lower tail of the PACE distribution. In the case of individual performance measures (SN, SP) or the composite AUC, one would be interested only in the upper tail of ACE. Symmetry is also known to be an especially important assumption when estimating the confi dence interval around the AUC (Efron and Tibshirani, 1993) .
The question of relative suitability of these alternatives should be determined empirically to determine if any practical differences exist in this particular application. So the question is posed: which statistical assessment of confi dence is of most practical (applied) interest: the specifi c measurement of classifi cation error achieved by x in the learning stage of the actual study, or the distribution of the classifi cation error in imagined alternative cases? We prefer to make our inferences on the data set at hand, for the time being, using imagined alternatives that involve a (hopefully) well-posed null condition. The bias-corrected accelerated bootstrap confi dence interval (Efron and Tibshirani, 1993) , which is range-respecting and rangepreserving (and unbiased, as the name suggests) corrects for differences between the median AUC of some of the pseudosamples and that of the original sample, making the imagined alternative samples more like the actual sample. This method should also be explored in this context. Some of these disparate methods could also potentially be combined (e.g, PACE as the null distribution and ROC bootstrapping to assess confi dence intervals around ACE). This would use the degree of overlap of distributions instead of specifi c instance outside of a generated distribution. A more formal exploration of these possibilities seems warranted.
Robustness of PACE and Permutation Approaches to the Stark Realities of High-Throughput Science
PACE provide a reference point that is robust to many of the vagaries in study design common to peptide profi ling studies, such as different numbers of technical replicates per sample that result from the application of QA/QC. Compared to distribution-dependent criteria that would otherwise require adjustments to degrees of freedom, both PACE and the bootstrap are relevant for the data set at hand.
Caveats
PACE and the other methods cited here do not protect incidental partial or complete confounding. True validation of the results of any high-throughput analysis should involve more than one site, ideally with the application of a specifi c classifi er rule learned at site A to data generated at site B. Further, to protect against amplifi cation of local biases by data preprocessing steps, the preprocessing must be wrapped within the permutation loop.
A Word on Coverage
It is important to consider in the development and evaluation of biomarker-based classifi cation rule whether a sample is classifi able; i.e, do the rules developed and data at hand provide suffi ciently precise information on a given sample. The proportion of samples that are predictable in a data is defined as coverage. If a strategy is adopted whereby a number of samples are not classifi ed, the evaluation scheme (whether it be a bootstrap, random subsampling-derived confi dence boundaries, or permutation signifi cance test) should also be forced to not classify the same number of samples. These 'enforced passes' on a sample must be checked and enforced after the prediction stage to conserve the numerical and statistical aspects of the study design and data set (e.g,s, number of samples; variability within m/z class).
Research is needed to determine the importance of asymptotic properties, dependencies of the bootstrap ROC on the monotonic or jaggedness of the ROC curve, and the use of combined distributions (i.e, measure of degree of overlap between the PACE distribution, as the null distribution, and the bootstrap ROC curve as variability in the estimated classifi er performance measure of interest in separate instance of the study).
Towards a More Complete Characterization of the Problem
In the consideration of further development and improvements in analytic methods for the analysis of peptide profiles, we assume that detailed descriptions of fundamental characteristics of lowresolution peptide profi les can be used to help set priorities in the construction of particular strategies. These descriptions/observations include • an acknowledgement of somewhat high mass accuracy (0.2-0.4%); • a comprehension that individual m/z values are not specifi c (i.e, they are not unique to individual peptides), and therefore intensity measures at a given m/z value refl ect sum intensity of 'peptide m/z classes', which may or may not be functionally associated; • an understanding that peptides do not map to single individual peptides; i.e, they exist two or more times in the profi le at different m/z values as variously protonated forms. Each peptide may have a roughly unique signature, and pattern matching forms the basis of peptide fi ngerprint data mining, but a peptide need not occur as a single peak; • an understanding that m/z variance will contain biological sources (mass shifts due to amino acid sequence variation and varying degrees of ubiquination and cleavage, binding of peptides with others), chemical, and physical components (mass drift), and thus models that allow the statistical accounting of each of these variance components are needed; • an understanding that high -intensity measurement in SELDI-TOF-MS profi les tend to exhibit higher variance, which suggest that reliance of peaks for any inference (analyzing peaks only, aligning peaks, or normalizing profi les to peaks) may add large, unwanted components of variance or restrict fi nding to peptides with intensities that are most inaccurately measured; • the acknowledgment that the m/z vector is an arbitrary vector along which intensity values of similarly massed and charged peptides are arranged, and, as an arbitrary index in and of itself may require (or deserve) no profound biological explanation and may or may not offer a profound biological insight related to the clinical questions at hand beyond a guide to identity of peptide by pattern matching; • observations that features determined to be signifi cant tend to be locally correlated and that long-range correlations also exist, and that both artifactual and biologically important correlations and anti-correlations may exist at both distances; • an expectation that correlations may exist that refl ect protonated forms of peptides and that some correlation/anticorrelation pairs may refl ect real peptide biology, such as enzymatic cleavage cascades; • similarly, the observation that at least part of the local autocorrelation observed in the profi le is likely due to poor resolution (mass drift), and reflects a physical property of the profiles (instrument measurement error and resolving power). It may also refl ect smoothing due to natural biological variation in the population from which the samples were drawn, the effects of summing intensities of distinct peptides that share similar but not identical m/z values. One might consider whether the local correlations all refl ect real biological properties of single peptides at particular m/z positions, and, if not, they may offer no biological insight and may require no biological explanation (i.e, local autocorrelation may be simple artifact of degree of resolution of the instrument and the lack of specifi city of m/z values).
These descriptions may help motivate research on variance corrections, de-correlation, the use of PCA, profi le alignment strategies, and attempts at transformation.
Other Open Questions
As high-throughput genomic and proteomic data become less expensive, and the laboratory equipment spreads into an increasing number of facilities, it seems likely that different laboratories will study the sample problem with completely independent effort. Published data sets, therefore, represent profoundly useful potential source of corroboration, or validation, of biomarker sets that might be expected to exhibit reproducible differences in large portions of the patient population. A careful characterization and validation of those differences, as a step that is independent of the question of potential clinical utility, is essential in these studies. True validation by planned repeated experiments may seem daunting, or unwarranted at this early stage, and the tendency will be to attempt to validate markers deemed to be significant in a small study using other technology (immunohistochemistry, for example). In this case, absence of validation of specifi c proteins with other technology is not complete refutation due to the potential for idiosyncrasies in this new application of mass spec technology. Computational validation applied at the step of feature selection alone could prove invaluable (i.e, which features are reproducibly different between cases and controls, responders and nonresponders, in independently analyzed subsets or splits of the data samples?)
Large multi-year and multi-site studies
As unlikely as large-scale repeated studies may seem, it seems imminent that studies of peptide profi les from thousands of patients and normal donors will be forthcoming. What are the practical problems in such a setting? We would advocate avoiding the temptation to view one large data set (say, 5,000 patient, 5,000 normal) as a single study, and would recommend analysis of multiple, random independent (non-overlapping) subsets, which would provide true validation of feature selection methods and classifi cation inferences. Such large studies will occur over long timer periods. Laboratory conditions change, and manufacturers change kits and protocols; thus, to maximize the generalizability of the performance characteristics of a trained classifi er, training and test sets should be randomly selected and blinded. We must remember that learning is asymptotic. Therefore, researchers should avoid evaluating a classifi er built on training data set 1 produced at time 1 with testing set produced at time 2; instead, they should randomize the data over the entire time period, even if this means re-learning a classifi er after publishing an initially internally valid classifi er using data set 1. This approach still involves training, but protects against a biased (overly pessimistic) result due to shifts in laboratory conditions.
Future Directions in Peptide Profi ling
Given that the distribution of pure noise variance over the m/z range is not uniform under the null condition, univariate feature selection methods such as t-tests, Fisher's score, area under the curve (AUC) and their nonparametric alternatives are perhaps best applied as permutation tests to attempt to equalize the Type 1 error rate over the m/z range included in an analysis. When combined with PACE, this greatly increases the computational burden of analyzing even a small set of profi les, but the pay-off should be immense. Features that are not signifi cant under the parametric, distributiondependent tests can become signifi cant under the permutation test for signifi cance, and the reverse shifts are also possible. This becomes especially important when using signifi cance levels to select n-ranked features. When permutation feature selection methods are then combined with classifi cation algorithms such as PCA, SVM, or nearest neighbor algorithms, and then are evaluated by PACE or bootstrap methods, this clearly will require a large network dedicated to cancer proteomic analysis, and a consortium of developers dedicated to bringing well-known existing and new algorithms for analysis to bear on the important problems in cancer research, including early detection, recurrence, progression and therapy outcome. A plan to use the rational unifi ed process outlined in caCORE (Covitz et al., 2003) as a software development protocol will help combine the energies of participants and developers in the Integrative Cancer Workspace of NCI's caBIG workspace with those of participants in the EDRN is under development. We intend to build a parallel-processing friendly analysis framework so researchers can objectively evaluate and report the effects of the decisions they make during each stage in analysis. Even so, support of analysis for small (pilot) studies is needed, and we can reasonably expect that optimal analysis solutions to vary with study design. The reanalysis of published data sets will also be key to sorting through the method space, so the design of such a solution might include data sets 'on-tap', as we have done for caGEDA (http://bioinformatics.upmc.edu/GE2/GEDA.html) for microarray data analysis (Patel and LyonsWeiler, 2004) . Simulations will also be key. We encourage sites to make their raw data (unpreprocessed) Figure D6 : PACE analysis using a SVM-based classifi er using the weighted separability scoring criterion, with a 0.6 MAC threshold. Left Panel: performance without peak selection. Right panel: performance with peak selection.
